Comparative study of intravenous ketorolac tromethamine and insertion of pancreatic duct stent to prevent post-ERCP pancreatitis : pilot study
Not Applicable
Not yet recruiting
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0000761
- Lead Sponsor
- Hallym University Medical Center-Kangnam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
patient with disease for which endoscopic retrograde cholangiopancreatogram is indicated for diagnosis or treatment
Exclusion Criteria
1) Unwillingness or inability to consent for the study
2) Age < 18 years or age=18 years or age >75 years
3) Intrauterine pregnancy
4) Breast feeding mother
5) Standard contraindications to ERCP
6) Allergy to Aspirin or NSAIDs
7) Renal failure (Cr > 1.4)
8) Active or recent (within 4 weeks) gastrointestinal hemorrhage
9) Existing acute pancreatitis within 72 hours prior to ERCP
10) Known chronic calcific pancreatitis
11) Pancreatic head malignancy
12) congenital anomaly of pancreatobiliary system
13) ERCP for biliary stent removal or exchange
14) Subjects with prior biliary sphincterotomy
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of post-ERCP pancreatitis
- Secondary Outcome Measures
Name Time Method side effects of ketorolac tromethamine and complications of insertion of pancreatic duct stent